Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Puromycin (Item No. 13884) is an aminonucleoside antibiotic that blocks protein synthesis in both prokaryotes and eukaryotes by causing premature termination of nascent polypeptide chains.1 Puromycin aminonucleoside (PANS) is the aminonucleoside portion of puromycin. This analog cannot inhibit protein synthesis or induce apoptosis. Instead it is used to induce nephropathy in laboratory animal models to study focal and segmental glomerulosclerosis, the induction of nephrosis, and the events leading to proteinuria.2 When administered to rats at 0.5-5 μM, PANS affects glomerular epithelial cell adhesion, reducing α3β1 integrin expression.3 PANS also has been shown to decrease nephrin and podocin expression.4
WARNING This product is not for human or veterinary use.
1. Mechanism of puromycin action: Fate of ribosomes after release of nascent protein chains from polysomes. Proc. Natl. Acad. Sci. USA 70(12), 3866-3869 (1973).
2. An evaluation of experimental models of glomerulonephritis. Int. J. Exp. Pathol. 75(1), 9-22 (1994).
3. Puromycin aminonucleoside suppresses integrin expression in cultured glomerular epithelial cells. J. Am. Soc. Nephrol. 12(4), 758-766 (2001).
4. Key molecular events in puromycin aminonucleoside nephrosis rats. Pathol. Int. 54(9), 703-711 (2004).